Background
cancers, tumor
CANCERS, TUMOR
Recent developments in molecular biology and genomics have enabled the classification of patients with common organ-specific cancers into several subpopulations depending on their molecular profiles derived using next-generation genomic sequencing. Clinical development of molecular targeted therapies has recently become pivotal and has been accelerated by the emergence of master protocol trials that assess the combination of several molecular markers and their targeted therapies by employing multiple sub-studies for single or multiple tumor types [Explicit control of the FWER at the target value is also important in basket trials, particularly in registration trials for drug approval [The proposed design is presented in the 